ascopubs.org

A phase II evaluation of sacituzumab govitecan in platinum-resistant ovarian cancer (NCT06028932).

Real-world outcomes of olaparib with versus without bevacizumab in bevacizumab-naïve BRCA1/2-mutated ovarian cancer. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract ...
ascopubs.org

How I Read a Clinical Trial Report? A Primer for Busy Clinicians

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted ...
ascopubs.org

Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?

Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making? The following represents disclosure information provided by authors of this ...
ascopubs.org

Effect of human-AI teams on oncology prescreening: Final analysis of a randomized trial.

A technology-enabled clinical trial program’s impact on patient screening and trial enrollment in 2024.
ascopubs.org

Use of local estrogen therapy among breast cancer patients in SEER-MHOS database.

Preoperative axillary US and MRI in early-stage breast cancer: Potential to prevent unnecessary axillary surgery. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
ascopubs.org

A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer.

Pattern of granulocyte colony stimulating growth factors (G-CSGF) usage in patients treated with sacituzumab govitecan: A real world multicenter study using the TriNetX database. This is an ASCO ...
ascopubs.org

Low-dose aspirin to reduce recurrence rate in colorectal cancer patients with PI3K pathway alterations: 3-year results from a randomized placebo-controlled trial.

A randomized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (CRC ...
ascopubs.org

Targeting DKK1 to Remodel the Tumor Microenvironment and Enhance Immune Checkpoint Blockade Therapy

DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish The following represents disclosure ...
ascopubs.org

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer—CDK4/6 Inhibitors: ASCO Rapid Guideline Update Clinical Insights

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
ascopubs.org

Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.

Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, ...
ascopubs.org

Comprehensive Recommendations for the Clinical Management of Pregnant Women With Noninvasive Prenatal Test Results Suspicious of a Maternal Malignancy

Supported in part by CAN.HEAL project (contract number 101080009, to J.R.V., F.A., and L.L.) under the EU4Health program. The following represents disclosure information provided by authors of this ...
ascopubs.org

Social Determinants of Health and Cancer Care: An ASCO Policy Statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...